{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:17:04Z","timestamp":1772165824865,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000199","name":"U.S. Department of Agriculture","doi-asserted-by":"publisher","award":["58-1950-4-003"],"award-info":[{"award-number":["58-1950-4-003"]}],"id":[{"id":"10.13039\/100000199","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007822","name":"Almond Board of California","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100007822","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Heart disease is the leading cause of death in the United States. The U.S. Food and Drug Administration approved the health claim that 1.5\u2009oz (42.5\u2009g) of nut intake may reduce the risk of cardiovascular disease. Previous studies have focused on the cost-effectiveness of other foods or dietary factors on primary cardiovascular disease prevention, yet not in almond consumption. This study aimed to examine the cost-effectiveness of almond consumption in cardiovascular disease primary prevention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Perspective &amp; Setting<\/jats:title>\n                    <jats:p>This study assessed the cost-effectiveness of consuming 42.5\u2009g of almond from the U.S. healthcare sector perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A decision model was developed for 42.5\u2009g of almond per day versus no almond consumption and cardiovascular disease in the U.S. population. Parameters in the model were derived from the literature, which included the probabilities of increasing low-density lipoprotein cholesterol, developing acute myocardial infarction and stroke, treating acute myocardial infarction, dying from the disease and surgery, as well as the costs of the disease and procedures in the U.S. population, and the quality-adjusted life years. The cost of almonds was based on the current price in the U.S. market. Sensitivity analyses were conducted for different levels of willingness-to-pay, the probabilistic sensitivity analysis, ten-year risk prevention, different costs of procedures and almond prices, and patients with or without cardiovascular disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The almond strategy had $363 lower cost and 0.02 higher quality-adjusted life years gain compared to the non-almond strategy in the base-case model. The annual net monetary benefit of almond consumption was $1421 higher per person than no almond consumption, when the willingness to pay threshold was set at $50,000 for annual health care expenditure. Almond was more cost-effective than non-almond in cardiovascular disease prevention in all the sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Consuming 42.5\u2009g of almonds per day is a cost-effective approach to prevent cardiovascular disease in the short term and potentially in the long term.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-020-08642-4","type":"journal-article","created":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T13:02:44Z","timestamp":1587819764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Daily almond consumption in cardiovascular disease prevention via LDL-C change in the U.S. population: a cost-effectiveness analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Jifan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle A.","family":"Lee Bravatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth J.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gowri","family":"Raman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,25]]},"reference":[{"issue":"Suppl 2","key":"8642_CR1","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1017\/S0007114514003729","volume":"113","author":"C Alasalvar","year":"2015","unstructured":"Alasalvar C, Bolling BW. Review of nut phytochemicals, fat-soluble bioactives, antioxidant components and health effects. Br J Nutr. 2015;113(Suppl 2):S68\u201378.","journal-title":"Br J Nutr"},{"key":"8642_CR2","doi-asserted-by":"crossref","unstructured":"Lee-Bravatti MA, Wang J, Avendano EE, King L, Johnson EJ, Raman G. Almond consumption and risk factors for cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. Adv Nutr. 2019.","DOI":"10.1093\/advances\/nmz043"},{"key":"8642_CR3","unstructured":"U.S. Food & Drug Administration. Qualified Health Claims: Letter of Enforcement Discretion - Nuts and Coronary Heart Disease (Docket No 02P-0505) 2003 . Available from: http:\/\/wayback.archive-it.org\/7993\/20171114183724\/https:\/\/www.fda.gov\/Food\/IngredientsPackagingLabeling\/LabelingNutrition\/ucm072926.htm."},{"issue":"10","key":"8642_CR4","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","volume":"139","author":"EJ Benjamin","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke Statistics\u20142019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56\u2013e528.","journal-title":"Circulation."},{"issue":"4","key":"8642_CR5","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.mayocp.2018.08.011","volume":"94","author":"R Cardoso","year":"2019","unstructured":"Cardoso R, Blumenthal RS, Kopecky S, Lopez-Jimenez F, Martin SS. How low to go with lipid-lowering therapies in a cost-effective and prudent manner. Mayo Clin Proc. 2019;94(4):660\u20139.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"8642_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","volume":"8","author":"BA Golomb","year":"2008","unstructured":"Golomb BA, Evans MA. Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8(6):373\u2013418.","journal-title":"Am J Cardiovasc Drugs"},{"key":"8642_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/JAA.S141636","volume":"11","author":"T Weinberger","year":"2018","unstructured":"Weinberger T, Sicherer S. Current perspectives on tree nut allergy: a review. Journal of asthma and allergy. 2018;11:41\u201351.","journal-title":"Journal of asthma and allergy"},{"issue":"11","key":"8642_CR8","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/ejcn.2013.184","volume":"67","author":"SY Tan","year":"2013","unstructured":"Tan SY, Mattes RD. Appetitive, dietary and health effects of almonds consumed with meals or as snacks: a randomized, controlled trial. Eur J Clin Nutr. 2013;67(11):1205\u201314.","journal-title":"Eur J Clin Nutr"},{"key":"8642_CR9","first-page":"Cd004816","volume":"1","author":"F Taylor","year":"2013","unstructured":"Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:Cd004816.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"8642_CR10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1001\/jama.2015.6822","volume":"314","author":"A Pandya","year":"2015","unstructured":"Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. Jama. 2015;314(2):142\u201350.","journal-title":"Jama."},{"key":"8642_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12937-015-0049-5","volume":"14","author":"CY Chen","year":"2015","unstructured":"Chen CY, Holbrook M, Duess MA, Dohadwala MM, Hamburg NM, Asztalos BF, et al. Effect of almond consumption on vascular function in patients with coronary artery disease: a randomized, controlled, cross-over trial. Nutr J. 2015;14:61.","journal-title":"Nutr J"},{"issue":"5","key":"8642_CR12","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1212\/WNL.0000000000001202","volume":"84","author":"A Pikula","year":"2015","unstructured":"Pikula A, Beiser AS, Wang J, Himali JJ, Kelly-Hayes M, Kase CS, et al. Lipid and lipoprotein measurements and the risk of ischemic vascular events: Framingham study. Neurology. 2015;84(5):472\u20139.","journal-title":"Neurology."},{"issue":"9","key":"8642_CR13","doi-asserted-by":"publisher","first-page":"641","DOI":"10.7326\/0003-4819-121-9-199411010-00002","volume":"121","author":"B Kinosian","year":"1994","unstructured":"Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med. 1994;121(9):641\u20137.","journal-title":"Ann Intern Med"},{"issue":"10","key":"8642_CR14","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","volume":"135","author":"EJ Benjamin","year":"2017","unstructured":"Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke Statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146\u2013603.","journal-title":"Circulation."},{"issue":"17","key":"8642_CR15","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1001\/jama.2011.551","volume":"305","author":"AJ Epstein","year":"2011","unstructured":"Epstein AJ, Polsky D, Yang F, Yang L, Groeneveld PW. Coronary revascularization trends in the United States, 2001-2008. JAMA. 2011;305(17):1769\u201376.","journal-title":"JAMA."},{"issue":"13","key":"8642_CR16","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1001\/archinte.165.13.1506","volume":"165","author":"MJ Eisenberg","year":"2005","unstructured":"Eisenberg MJ, Filion KB, Azoulay A, Brox AC, Haider S, Pilote L. Outcomes and cost of coronary artery bypass graft surgery in the United States and Canada. Arch Intern Med. 2005;165(13):1506\u201313.","journal-title":"Arch Intern Med"},{"issue":"8","key":"8642_CR17","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1212\/01.wnl.0000254472.41810.0d","volume":"68","author":"T Kurth","year":"2007","unstructured":"Kurth T, Everett BM, Buring JE, Kase CS, Ridker PM, Gaziano JM. Lipid levels and the risk of ischemic stroke in women. Neurology. 2007;68(8):556\u201362.","journal-title":"Neurology."},{"issue":"10","key":"8642_CR18","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1161\/STROKEAHA.107.487090","volume":"38","author":"JD Sturgeon","year":"2007","unstructured":"Sturgeon JD, Folsom AR, Longstreth WT Jr, Shahar E, Rosamond WD, Cushman M. Risk factors for intracerebral hemorrhage in a pooled prospective study. Stroke. 2007;38(10):2718\u201325.","journal-title":"Stroke."},{"key":"8642_CR19","unstructured":"Trader Joe\u2019s. Raw Clifornia almonds 2018 . Available from: https:\/\/www.traderjoes.com\/FearlessFlyer\/Article\/4441#.XFCA15VZBfc.email=0A=0ATo."},{"key":"8642_CR20","unstructured":"Nuts.com. Organic Almonds (Raw, No Shell) . Available from: https:\/\/nuts.com\/nuts\/almonds\/organic.html."},{"issue":"2","key":"8642_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/ccd.23147","volume":"79","author":"DJ Cohen","year":"2012","unstructured":"Cohen DJ, Lavelle TA, Van Hout B, Li H, Lei Y, Robertus K, et al. Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or three-vessel coronary artery disease: one-year results from the SYNTAX trial. Catheter Cardiovasc Interv. 2012;79(2):198\u2013209.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"6","key":"8642_CR22","doi-asserted-by":"publisher","first-page":"e98371","DOI":"10.1371\/journal.pone.0098371","volume":"9","author":"T Caruba","year":"2014","unstructured":"Caruba T, Katsahian S, Schramm C, Charles Nelson A, Durieux P, Begue D, et al. Treatment for stable coronary artery disease: a network meta-analysis of cost-effectiveness studies. PLoS One. 2014;9(6):e98371.","journal-title":"PLoS One"},{"key":"8642_CR23","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2147\/VHRM.S10851","volume":"6","author":"NM Engel-Nitz","year":"2010","unstructured":"Engel-Nitz NM, Sander SD, Harley C, Rey GG, Shah H. Costs and outcomes of noncardioembolic ischemic stroke in a managed care population. Vasc Health Risk Manag. 2010;6:905\u201313.","journal-title":"Vasc Health Risk Manag"},{"key":"8642_CR24","unstructured":"Russo CA, Andrews RM. Hospital Stays for Stroke and Other Cerebrovascular Diseases, 2005: Statistical Brief #51. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006."},{"issue":"7","key":"8642_CR25","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1161\/CIRCULATIONAHA.112.147488","volume":"127","author":"EA Magnuson","year":"2013","unstructured":"Magnuson EA, Farkouh ME, Fuster V, Wang K, Vilain K, Li H, et al. Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial. Circulation. 2013;127(7):820\u201331.","journal-title":"Circulation."},{"issue":"23","key":"8642_CR26","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1161\/01.CIR.0000103121.26241.FA","volume":"108","author":"A Bakhai","year":"2003","unstructured":"Bakhai A, Stone GW, Grines CL, Murphy SA, Githiora L, Berezin RH, et al. Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (controlled Abciximab and device investigation to lower late angioplasty complications) trial. Circulation. 2003;108(23):2857\u201363.","journal-title":"Circulation."},{"issue":"17","key":"8642_CR27","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1212\/WNL.0b013e318234332d","volume":"77","author":"RE Nelson","year":"2011","unstructured":"Nelson RE, Saltzman GM, Skalabrin EJ, Demaerschalk BM, Majersik JJ. The cost-effectiveness of telestroke in the treatment of acute ischemic stroke. Neurology. 2011;77(17):1590\u20138.","journal-title":"Neurology."},{"issue":"1","key":"8642_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2165\/00019053-200725010-00002","volume":"25","author":"RL Fleurence","year":"2007","unstructured":"Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling: transformation, translation and appropriate application. PharmacoEconomics. 2007;25(1):3\u20136.","journal-title":"PharmacoEconomics."},{"key":"8642_CR29","unstructured":"Centers for Medicare & Medicaid Services. Table 23 National Health Expenditures; Nominal Dollars Real Dollars Price Indexes and Annual Percent Change 2018 . Available from: https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/NationalHealthExpendData\/Downloads\/Tables.zip."},{"key":"8642_CR30","unstructured":"Statistics BoL. CPI Inflation Calculator N.D. . Available from: https:\/\/data.bls.gov\/cgi-bin\/cpicalc.pl."},{"issue":"9","key":"8642_CR31","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness \u2014 the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796\u20137.","journal-title":"N Engl J Med"},{"issue":"2","key":"8642_CR32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1586\/14737167.8.2.165","volume":"8","author":"SD Grosse","year":"2008","unstructured":"Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165\u201378.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"8642_CR33","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1177\/0272989X0002000310","volume":"20","author":"RA Hirth","year":"2000","unstructured":"Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3):332\u201342.","journal-title":"Med Decis Making"},{"issue":"4","key":"8642_CR34","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/MLR.0b013e31815c31a7","volume":"46","author":"RS Braithwaite","year":"2008","unstructured":"Braithwaite RS, Meltzer DO, King JTJ, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46(4):349\u201356.","journal-title":"Med Care"},{"key":"8642_CR35","unstructured":"World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis. Switzerland 2003. Available from: https:\/\/www.who.int\/choice\/publications\/p_2003_generalised_cea.pdf."},{"issue":"5","key":"8642_CR36","first-page":"521","volume":"8","author":"S Ramsey","year":"2005","unstructured":"Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA. Task Force report. 2005;8(5):521\u201333.","journal-title":"Task Force report"},{"issue":"5","key":"8642_CR37","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1111\/j.1523-1755.2004.00950.x","volume":"66","author":"PA McFarlane","year":"2004","unstructured":"McFarlane PA, Bayoumi AM. Acceptance and rejection: cost-effectiveness and the working nephrologist. Kidney Int. 2004;66(5):1735\u201341.","journal-title":"Kidney Int"},{"key":"8642_CR38","unstructured":"National Center for Health S. Health, United States. Health, United States, 2016: With Chartbook on Long-term Trends in Health. Hyattsville (MD): National Center for Health Statistics (US); 2017."},{"issue":"1","key":"8642_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1478-7547-12-4","volume":"12","author":"MC Gulliford","year":"2014","unstructured":"Gulliford MC, Bhattarai N, Charlton J, Rudisill C. Cost-effectiveness of a universal strategy of brief dietary intervention for primary prevention in primary care: population-based cohort study and Markov model. Cost Eff Resour Alloc. 2014;12(1):4.","journal-title":"Cost Eff Resour Alloc"},{"issue":"4","key":"8642_CR40","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.clinthera.2017.02.012","volume":"39","author":"SR Earnshaw","year":"2017","unstructured":"Earnshaw SR, McDade CL, Chu Y, Fleige LE, Sievenpiper JL. Cost-effectiveness of maintaining daily intake of oat beta-Glucan for coronary heart disease primary prevention. Clin Ther. 2017;39(4):804\u201318 e3.","journal-title":"Clin Ther"},{"issue":"7","key":"8642_CR41","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s10198-017-0934-2","volume":"19","author":"W Yang","year":"2018","unstructured":"Yang W, Gage H, Jackson D, Raats M. The effectiveness and cost-effectiveness of plant sterol or stanol-enriched functional foods as a primary prevention strategy for people with cardiovascular disease risk in England: a modeling study. Eur J Health Econ. 2018;19(7):909\u201322.","journal-title":"Eur J Health Econ"},{"issue":"9359","key":"8642_CR42","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0140-6736(03)12655-4","volume":"361","author":"CJ Murray","year":"2003","unstructured":"Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet. 2003;361(9359):717\u201325.","journal-title":"Lancet."},{"issue":"3","key":"8642_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002761","volume":"16","author":"Y Lee","year":"2019","unstructured":"Lee Y, Mozaffarian D, Sy S, Huang Y, Liu J, Wilde PE, et al. Cost-effectiveness of financial incentives for improving diet and health through Medicare and Medicaid: a microsimulation study. PLoS Med. 2019;16(3):e1002761.","journal-title":"PLoS Med"},{"key":"8642_CR44","unstructured":"Economic Research Service. Fruit and Tree Nut Yearbook Tables United States Department of Agriculture,: United States Department of Agriculture,; 2018 . Available from: https:\/\/www.ers.usda.gov\/data-products\/fruit-and-tree-nut-data\/fruit-and-tree-nut-yearbook-tables\/#Tree%20Nuts."}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-08642-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-020-08642-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-08642-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T19:13:47Z","timestamp":1619291627000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-020-08642-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,25]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["8642"],"URL":"https:\/\/doi.org\/10.1186\/s12889-020-08642-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.11042\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.11042\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.11042\/v3","asserted-by":"object"}]},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,25]]},"assertion":[{"value":"25 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ethics approval was not necessary for this study as the data were publicly available in published articles or were obtained through request from Dr. Tan [\n                      \n                      ] and Dr. Chen [\n                      \n                      ]. No patient-level data were included.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"G.R. was a consultant for Porter Novelli and E.J.J. had additional funds from the Almond Board of California for a clinical trial at the time of the study. Other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"558"}}